Cite

HARVARD Citation

    Nakajima, H. et al. (2022). Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer. Breast. pp. 136-144. [Online]. 
  
Back to record